[Treatment of chronic hepatitis C in haemophilia patients].
Adults with inherited disorders of coagulation have one of the highest prevalence rates of hepatitis C among known risk groups. Few data are available on the use of combination therapy with interferon and ribavirin in this population. The patients had HCV RNA detectable in serum by polymerase chain reaction, elevated serum aminotransferase (more than 100 U/l). Liver biopsy was not performed. The treatment with interferon alfa 2 b 3 x 3 million units weekly and ribavirin 800 mg/day for 48 weeks. 19 patients were treated and the sustained virological response was 40% (8 of 19). Hemoglobin mean values decreased during treatment, nevertheless all patients were able to finish treatment with small dose adjustments. The re-treatment of 4 nonrespondent patients (interferon and ribavirin) treated again with Peg-interferon alfa 2 b plus ribavirin proved ineffective too.
Ibrányi
Endre
E
Fovárosi Szent László Kórház, IV. Fertozo Belgyógyászat, Budapest.
Nemes
László
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006467:Hemophilia A / Q000150:complications*; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000302:isolation & purification; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a